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Abstract
Multiple sclerosis (MS) is the most important immune-mediated demyelinated 
disease of human which is typically the disease of young adults. A total of 4% 
to 5% of MS population are pediatric. Pediatric MS is defined as the appearance 
of MS before the age of sixteen. About 80% of the pediatric cases and nearly all 
adolescent onset patients present with attacks typical to adult MS. Approximately 
97% to 99% of the affected children have relapsing-remitting MS, while 85% to 
95% of the adults experience such condition. MS in children is associated with 
more frequent and severe relapses. Treatment is the same as adults. We aimed 
to review the epidemiology, etiology, clinical manifestations, and treatment of 
MS in children. 
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Introduction
History 
Multiple sclerosis (MS) is the most important immune-mediated demyelinated 
disease of the human-beings (1). The earliest record of MS dates back to 1837, 
when Carswell and Cruveilhier separately described the histological lesions of 
MS in the central nervous system (CNS) (1,2). Frerichs was the first who made the 
clinical diagnosis of MS in the patients in 1840. A few years later, Kobat identified 
abnormal oligocloncal bands in the spinal fluids of the MS patients (3). In 1868, 
Charcot was the first who described associations between the symptoms of MS 
and the pathological changes in postmortem samples (4). In 1965, National MS 
Society set up a panel of professionals in order to provide a standard guideline for 
MS diagnosis (1). In 1916, Dawson provided the definite histological account of 
the disease (5). 
Several retrospective studies were published in 1968 and 1990 revealing that 
some adults with MS had neurological symptoms since adolescence (6). MS is 
typically the disease of young adults. Pediatric MS is defined as the appearance of 
MS before the age of sixteen. Its prevalence varies by geographic region ranging 
from 1.35 to 2.5 per 100.000 in United State to over 248 per 100.000 in western 
Canada (7,8). About 5% of the patients present before the age of 16 years and less 
than 1%, before the age of 10 (6,9). 
Female to male ratio varies by age and is 0.8:1 under 6 years of age, 1.6:1 between 
6 and 10 years, 2.1:1 over 10 years, and 3:1 in adolescence. The most prevalent 
age of presentation in children is about 12 to13 years (8,10). 
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Pathogenesis 
The disease is a dysregulation of immune system that 
leads to CNS injury. Both genetic susceptibility and 
environmental factors are required for the initiation of 
the disease. It is believed that development of MS occurs 
in the individuals who are genetically susceptible and 
exposed to triggers during the vulnerability period. 
Genetic Susceptibility 
Monozygote twins studies show a 25-percent 
concordance for the development of MS. The risk 
rate in dizygote twins is similar to that of first-degree 
relatives being almost 2% to 5% (11,12). It has also 
been shown that certain Human Leukocyte Antigen 
(HLA) genes including HLA-DRB1, 1501, DQA 0102, 
and DQB1 0602 are associated with increased risk of 
MS. HLA DR15 has strongly been associated with 
early-onset MS (11,13). 
Environmental factors 
Environmental exposure to hundreds of viral and 
bacterial pathogens such as ebstein barr virus (EBV) is 
linked to MS. The nuclear antigen of EBV is structurally 
similar to myelin basic protein, the main component of 
CNS myelin. T cell activated EBV antigen may damage 
this protein because of the similarity between these two 
antigens. Many studies revealed that the adults with 
MS were almost 100% seropositive for EBV infection, 
as well (14). 
Serologic evidence of past EBV infection was 86% 
in MS children compared to 64% in normal children 
(15,16). A 70-percent decreased rate of MS in remote 
infection with cytomegalovirus (CMV), 70-percent 
decreased rate in remote infection with herpes virus 
types 1 in HLA-DRB1 positive patients, and an almost 
4-fold decreased rate of the disease in HLA DRB1 
negative people are suggestive of gene-environmental 
interactions (17). Although it is said that vaccination 
may increase the risk of MS, evidence supports no 
association between vaccination and MS in adults 
(18). Also, it has been proved that vaccination against 
hepatitis B is not associated with increased risk of 
childhood MS (19).
The disease is more prevalent at more northern 
latitudes. Migration studies found that individuals who 
immigrated to high-risk areas in childhood show the 
risk rate of the new countries rather than the risk of 
their original countries. Risk of MS among migrants is 
shown to be influenced by the age at migration with the 
critical period being prior to the age of 15 years (20). 
Some studies have revealed negative correlation 
between vitamin D (Vit D) levels and the risk of 
developing MS. Vitamin D is biosynthesized by 
cutaneous exposure to sunlight. It is known to have 
immuno-regulatory effects including enhancement 
of the T-cell activity regulation, up-regulation of 
anti-inflammatory molecules, and down-regulation 
of pro-inflammatory cytokines. Some experiments 
demonstrated the important prenatal effects of vitamin 
D on the regulation of the normal immune system 
persisting for the life time (21). Risk of MS is greater 
in individuals born in May and lower in those born in 
November. This finding suggests that pregnancy during 
winter with less sunlight exposure may accompany 
adverse effect on fetal normal production of vitamin 
D (22). A small study in pediatric MS found that high 
circulating levels of vitamin D decreased the attack 
rates (23). Low levels of vitamin D have been identified 
as a risk factor of pediatric MS; however, the specific 
role of this risk factor is still not understood (24).
Smoking raises the risk of MS in adults. Similarly, 
passive smoking has been shown to increase the risk of 
pediatric MS by 2 times (25). Female obesity at the age 
of 18 is another risk factor known to increase the risk 
of MS by 2 folds (26). 
Clinical manifestations
The disease is characterized by multiple episodes of 
demyelination in critical areas of CNS (brain, optic 
nerves, spinal cord) separated with time intervals of at 
least 30 days.
Clinical features of pediatric and adult MS are similar; 
however, optic neuritis, isolated brain stem syndrome or 
symptoms of encephalopathy like headache, vomiting, 
seizure and/or altered consciousness are more common 
in children (27). 
Approximately 97% to 99% of the affected children 
and almost 85% to 95% of the adults have relapsing-
remitting MS (RRMS). Primary progressive MS (PPMS) 
is rare in children, and therefore, leukodystrophy, 
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Multiple Sclerosis in Children
inborn error of metabolism, mitochondrial diseases, 
and neuromyelitis optica that can be misdiagnosed as 
MS should be ruled out in every child with continuous 
disability without specific attacks (28,29). 
Diagnostic criteria
Until 2006, Poster criteria were used for the diagnosis 
of pediatric MS. This was then replaced by “McDonald 
criteria” being introduced in 2001 and revised in 2005 
and 2010 (30-32) (Table1). Core of the criteria is the 
disseminated lesions based on clinical and finding of 
the magnetic resonance imaging (MRI) (33). However, 
nowadays, Poster criteria are only used in countries 
where MRI is not available (34). 
Table 1. The 2010 McDonald Criteria for Diagnosis of Pediatric MS (35)*
Clinical presentation Additional data needed for MS diagnosis
 2 attacksa; objective clinical evidence of 
>2 lesions or objective clinical evidence 
of 1 lesion with reasonable historical 
evidence of a prior attackb
Nonec
 2 atracksa; objective clinical evidence of 
one lesion
Dissemination in space, demonstrated by:
1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord)d: or Await a 
further clinical attacka implicating a different CNS site
1 attacka: objective clinical evidence 
of 2 lesions
Dissemination in time, demonstrated by:
Simultaneous presence of asymptomatic gadolinium-enhancing and non 
enhancing lesions at any time: or
A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan; or Await a 
second clinical attacka
1 attacka: objective clinical evidence of 1 
lesion (clinically isolated syndrome)
Dissemination in space and time, demonstrated by:
For DIS:
1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, Juxtacortical, infratentorial, or spinal cord)d; or Await a 
second clinical attacka implicating a different CNS site: and
For DIT:
Simultaneous presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions at any time; or
A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI 
irrespective of its timing with reference to a baseline scan; or
Await a second clinical attacka
Insidious neurological progression 
suggestive of MS (PPMS)
One year of disease progression (retrospectively or prospectively 
determined) plus 2 of 3 of the following criteriad:
1. Evidence for DIS in the brain based on 1 T2 lesions in the MS 
characteristic (periventricular, juxtacortical, or infratentorial) region
2. Evidence for DIS in the spinal cord based on 2 T2 lesions in the cord
3. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/
or elevated IgG index)
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If the Criteria are fulfilled and there is no better explanation for the clinical presentation, the diagnosis is “MS”; if suspicious, 
but the Criteria are not completely met, the diagnosis is “possible MS”; if another diagnosis arises during the evaluation that 
better explains that clinical presentation, then the diagnosis is “not MS.”
a An attack (relapse; exacerbation) is defined as patient reported or objectively observed events typical of an acute inflammatory 
demyelinating event in the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or infection. 
It should be documented by contemporaneous neurological examination, but some historical events with symptoms and 
evolution characteristic for MS, but for which no objective neurological findings are documented, can provide reasonable 
evidence of a prior demyelinating event. Reports of paroxysmal symptoms (historical or current) should, however, consist 
of multiple episodes occurring over not less than 24 hours. Before a definite diagnosis of MS can be made, at least 1 attack 
must be corroborated by findings on neurological examination, visual evoked potential response in patients reporting prior 
visual disturbance, or MRI consistent with demyelination in the area of the CNS implicated in the historical report of 
neurological symptoms.
b Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past 
attack in the absence of documented objective neurological findings, can include historical events with symptoms and 
evolution characteristics for a prior inflammatory demyelinating event; at least 1 attack, however, must be supported by 
objective findings.
c No additional tests are required. However, it is desirable that any diagnosis of MS be made with access to imaging based on 
these criteria. If imaging or other tests (for instance, analysis of CSF) are undertaken and are negative, extreme caution 
needs to be taken before making a diagnosis of MS, and alternative diagnoses must be considered. There must be no better 
explanation for the clinical presentation, and objective evidence must be present to support a diagnosis of MS.
d Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration in subjects with brain 
stem or spinal cord syndromes.
MS= multiple sclerosis; CNS= central nervous system; MRI= magnetic resonance imaging; DIS= dissemination in 
space; DIT dissemination in time; PPMS= primary progressive multiple sclerosis; CSF= cerebrospinal fluid; IgG= 
immunoglobulin G.
McDonald criteria should not be used as diagnostic 
criteria for children presenting with encephalopathy and 
multifocal neurological deficit (35). 
A total of 15% to 20 % of MS children present 
with the symptoms similar to acute disseminated 
encephalomyelitis (ADEM). Most of such children are 
younger than 11 years. 
Typical lesions of ADEM are poorly demarginated 
in deep and sub-cortical white matter and generally 
bilateral. Children with early onset MS (at age younger 
than 11 years) have larger and less well-defined lesions 
when compared with typical brain lesions in teenagers 
and adults. Application of McDonald criteria in these 
children with such lesions, specially with symptoms of 
encephalopathy, is thus inappropriate and continuous 
follow-up is needed to confirm both clinical and MRI 
findings for the diagnosis of MS (36,37). Current 
consensus criteria for MS diagnosis in children with an 
ADEM-like first attack need confirmation by two or more 
non ADEM-like attacks or one non ADEM-like attack 
followed by clinically silent lesion (38). Also in children 
presented with insidious neurological progression and 
considered as primary progressive MS (PPMS), criteria 
is different (Table 1) (39-41). 
Clinically isolated syndrome (CIS) is a single attack 
compatible with MS and one type of symptoms such as 
optic neuritis. About 80% of pediatric MS cases present 
with attacks similar to adult CIS (42-44). Episodes of 
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CIS are diagnostic and therapeutic challenges. Majority 
of the children do not experience the second attack. In 
such a situation, clinical investigations including brain 
MRI, CSF analysis and other laboratory studies can 
differentiate the high-risk and low-risk groups regarding 
recurrence. A series of factors including age of 10 years 
and older, optic nerve lesion, and typical MS lesions in 
the MRI (typical well-defined lesions in periventricular 
or subcortical areas) are believed to increase the risk of 
recurrence (45). Spinal cord lesions and acute mental 
status change may-on the other hand- decrease the risk 
of second attacks. 
MRI findings in MS 
1. Multiple well-demarcated lesions in the periventricular, 
subcortical, infratentorial, and spinal cord white matter 
that are better diagnosed on T2 weighted sequences and 
T2 fluid attenuated inversion recovery (FLAIR). FLAIR 
sequences are the most sensitive in the evaluation of 
lesions especially in the periventricular lesions. 
2. “Black holes” on T1 weighted sequences representing 
complete tissue loss due to previous inflammatory 
lesions. 
3. Enhancement of active area of inflammation and 
blood-brain barrier compromise on T1 gadolinium 
contrast sequences. 
Pediatric MS accompanies more T2 bright lesions in 
the posterior fossa and more gadolinium enhancement 
lesions than in adults. Lesions are more reversible on 
follow-up imaging in children and suggest a better 
recovery course (41). MS in children also appears to be a 
highly inflammatory disease with more frequent relapses 
compared to adults (43).
CSF analysis 
A CSF analysis is defined to be positive for MS if 
oligoclonal IgG bands (OCBs) or increased IgG index 
are present. The 2001 and 2005 McDonald criteria 
mentioned that positive CSF and new lesions on serial 
MRI were enough for confirmation of the diagnosis of 
MS even in patients with a single clinical attack (30). 
However, this was not considered in the diagnosis by the 
2010 criteria except for the diagnosis of PPMS.
CSF profile in pediatric MS is different from adults. 
Positive OCBs, elevated IgG index, and pleocytosis 
have been reported in 8% to 92%, 64% to 75%, and 
33% to 73% of the MS children, respectively (46). 
Evoked potentials
Visual evoked potentials (VEP) and somatosensory 
evoked potentials (SSEP) provide supportive 
evidence for demyelination in the optic nerve, and 
brain stem or spinal cord and help diagnosis of MS; 
however, their utility in confirming the diagnosis is 
not yet established (47,48). 
Treatment
Acute attack: Glucocorticoids are the main 
treatment of acute attacks. Intravenous (IV) pulse 
of methylprednisolone (20 to 30 mg/kg, daily, 
for five days) is a typical regimen. No further 
glucocorticoid is needed if patients recover 
completely. However, oral prednisolone starting 
with 1 mg/kg/day and decreasing by 5 mg every 
two days is used for the patients with residual 
disability. For patients who experience recurrence 
during glucocorticoid tapering, repeated treatment 
with IV methylprednisolone with the same doses 
is suggested. Intravenous immune globulin (IVIG) 
(400 mg/kg/day for 5 days) can be used for the 
patients refractory to glucocorticoids or during 
febrile illnesses when infection is suspected or if 
there is contraindication for steroid consumption 
(49,50). Plasmapheresis (plasma exchange) is 
reserved to be used in severe fulminant relapses 
refractory to treatment with steroid or intravenous 
immunoglobulin (51).
 
Long term treatment: Immunomodulating agents 
including interferon beta drugs (interferon beta-
1a and 1b) and glatiramer acetate are used to 
prevent relapses or progression of MS. In adults, 
these agents reduce the recurrence rate of MS by 
30%. However, no randomized controlled trials 
have been done to elucidate the effect of these 
treatments on MS children. Nevertheless, different 
drug regimens in pediatric patients have been 
shown to decline the recurrence rate and slow the 
progression of MS.
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suggests baseline neurological examination followed 
by examinations on the first, third, and sixth months of 
therapy and every six months, afterwards. Annual MRIs 
are considered by many neurologists. 
For the patients with progressive symptoms or diffused 
lesions on brain MRI compared to the baseline scan, 
the therapeutic regimen should be changed and a more 
aggressive treatment should be started (55). 
Refractory MS is defined as the occurrence of three or 
more relapses in a 12-month period, significant increase 
in MRI lesions, or progression of disability in spite of 
immunomodulatory therapy. 
If the patients do not respond to Avonex therapy and 
show disease progression, the treatment regimen can 
be changed to higher doses of interferon beta (Rebif 
or Betaseron) or glatiramer acetate. Poor responses 
to high dose interferon can be replaced by glatiramer 
acetate. However, for patients with progressive diseases 
on high-dose interferon beta or glatiramer acetate, 
immunosuppressive medications such as mitoxantrone 
(anthracycline agent) or cyclophosphamide or rituximab 
or daclizumab can also be added (56,57). 
Although no evidence supports the effectiveness of these 
drugs in pediatric MS, in fulminant or aggressive MS 
mitoxantrone can be used with dose of 12 mg/m2, IV, 
every 3 months for 2 years. Lifelong cumulative dose 
should not be more than 140 mg/m2. Considering its 
cardiac toxicity, use of mitoxantrone should be limited 
to pediatric patients with rapidly advancing disease and 
no response to other therapies. 
Natalizumab- a recombinant humanized monoclonal 
antibody- has been recently approved as monotherapy 
in adults with RRMS but not for children yet. In only 
one pediatric study carried out in Italy, natalizumab (300 
mg/day, every 28 days) was used in 19 children with 
severe active MS. During a 15-month period of follow-
up relapses and MRI lesions suppressed in all patients 
and no serious side effects were reported. However, 
this medication has not yet been approved to be used in 
pediatric MS patients (58). High-dose cyclophosphamide 
followed by autologous haematopoietic stem cell 
transplantation (AHSCT) is also a new treatment 
option for aggressive and refractory MS and showed 
progression-free survival proportion between 50 and 
77% in short term in adult (59). Oral agents including 
Drug dose: 
 Interferon beta-la (Avonex): 30 mcg/ intramuscular 
(IM)/ once weekly;
 Interferon beta-1a (Rebif): 22 or 44mcg/ subcutaneous 
(SC)/ three times a week;
 Interferon beta-1b (betaferon): 8 million international 
units/ SC/ every other day;
 Glatiramer acetate: 20 mg/ SC/ daily. 
The recommended doses of these drugs are similar in 
both adults and adolescents heavier than 50 kg; but, for 
children less than 10 years of age, the dose is calculated 
based on the child weight in kilograms divided by 50kg 
and multiplying the results by adult dose (52-55).
Side effects 
1. Glatiramer acetate 
The most common side effect is transient skin reactions 
at the site of the injection that resolve with continuing 
the treatment. Chest pain and flushing are also of the 
other transient complications occurring immediately 
after the injection. 
2. Interferon 
The most common side effects are flue-like syndrome, 
headache, transient elevation of the liver enzymes, 
leucopenia, anemia, thrombocytopenia, and thyroid 
dysfunction mandating regular monitoring during the 
treatment courses. Abnormalities often resolve with 
dose reduction. 
Interferon beta-la (Avonex) is often preferred in 
children because of its weekly injection dose. It is also 
recommended for the patients with less frequent attacks, 
low-density brain lesions, and no disability. 
Glatiramer acetate, Betaferon, and Rebif are suggested 
for the patients with the history of more than one attack 
in a year, those with fixed disabilities, and those with 
many brain lesions (plaque) or atrophy on MRI.
Interferon beta treatment is better to be avoided in 
the patients with depression because of exacerbating 
depression symptoms. In such patients, glatiramer 
acetate is preferable. Besides, it is recommended for the 
patients who experience liver enzymes abnormalities 
following interferon injection. 
Patients’ clinical signs and symptoms as well as 
their neuroimaging parameters should be regularly 
monitored. The international pediatric MS study group 
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fingolimod and teriflunomide have been approved 
by FDA to be used in adult relapsing – remitting MS; 
however, they have been accompanied by serious side 
effect including lethal herpetic infection, cancer, and 
cardiac death. There is no study to evaluate the use of 
fingolimod in pediatric MS population (51).
Supportive and symptomatic therapy 
Symptomatic treatments help improve the quality of 
life in the patients. Fatigue is one of the most common 
complaints of the MS cases which may be due to the 
demyelinated nerve fibers, depression, or daily stresses 
at school or work. Depressed patients should be referred 
to psychiatrists and receive treatment. However, the 
most common cause of fatigue is the disease itself 
(60). Occupational therapy may be useful to relieve it. 
Medications such as amantadine, modafinil, fluoxetin, 
and methylphenidate are also helpful. Amantadine and 
modafinil are typically the first-line treatment options. 
The recommended dose of amantadine is 2.5 mg/kg, 
twice a day (maximum dose of 150 mg) for children 
under 40 kg or younger than 10 years of age and 100 
mg, twice a day for the older children and adults. The 
dose can be increased to total 400 mg if needed. 
Modafinil is started with the dose of 50 to100 mg once 
a day for children under 10 years and 100 mg/day for 
older ones. The dose is increased to 300 mg/day if 
needed (61). 
Methylphenidate and other amphetamines are given 
at doses similar to those used for attention deficit 
hyperactive disorder (62).
Fluoxetine is started at the dose of 10 mg every other 
day for 2 weeks and then increased to 20 mg/day 
for children under 10 years and up to 40 mg/day for 
adolescents. Fluoxetine should be used cautiously in 
depressed patients because it sometimes increases the 
suicide tendency. Child psychiatrists should therefore 
be consulted in children and adolescents with evidences 
of mood disorder presentations. 
Cognitive impairments are common in adult with MS 
and may also bee seen in MS children. The severity of 
such symptoms depends on the duration and severity of 
MS and may involve language, visuomotor integration, 
and verbal and visual memory (62). 
Prognosis
Disability due to MS is highly variable in the patient; 
but, the progression is usually very slow. A total of 
97% to 99% of the pediatric MS population experience 
relapsing, remitting courses and only 1% to 2% of 
childhood-onset MS has progressive course. 
Several studies showed that a younger age at MS onset 
is associated with slower disease progression. However, 
patients with pediatric-onset MS developed disability at 
younger ages compared to those with adult-onset MS 
because of a longer duration of disease and early-onset 
presentation of the disease. 
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